FARN:LON
Faron Pharmaceuticals Oy
36,07 GBX
arrow_downward
−1,18%(−0,43) 1 D.
10-01, 17:44:12 GMT+1 · GBX
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „FARN“ įžvalgos...
Atidaryti
37,75 GBX
Aukšta
38,00 GBX
Žema
34,00 GBX
Rinkos kapitalizacija
73,18 mln.
Vid. kiekis
49,09 tūkst.
Apimtis
95,17 tūkst.
52 sav. aukšta
193,58 GBX
52 sav. žema
34,00 GBX
Pajamos iš vienos akcijos
−0,10 GBX
Neapmokėtos akcijos
31,03 mln.
Darbuotojų skaičius
36
Atidaryti
37,75 GBX
Aukšta
38,00 GBX
Žema
34,00 GBX
Rinkos kapitalizacija
73,18 mln.
Vid. kiekis
49,09 tūkst.
Apimtis
95,17 tūkst.
52 sav. aukšta
193,58 GBX
52 sav. žema
34,00 GBX
Pajamos iš vienos akcijos
−0,10 GBX
Neapmokėtos akcijos
31,03 mln.
Darbuotojų skaičius
36
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Yahoo Finance
·
prieš 39 minutes
Dow, S&P 500, Nasdaq Futures Rise Ahead Of Key Jobs Report: NKE, NFLX, BABA, XRPN Stocks In Focus
KSLM Radio
·
prieš 33 minutes
Australia’s Sunrise Energy Metals plans US redomicile, primary Nasdaq listing
FXStreet
·
prieš 29 minutes
Elliott Wave outlook: Dow futures (YM) bearish sequence targets 49570 [Video]
Investor's Business Daily
·
prieš 30 minučių
Futures Await Jobs, Tesla; Micron Flashes Buy Signal
Profilis
Faron Pharmaceuticals is a Finnish drug discovery and development company based in Turku, Finland.
The company was founded in 2003 by a group led by Markku Jalkanen, who now acts as the company's Chief Executive Officer. It specialises in the development of treatments for acute organ traumas, vascular damage and cancer immunotherapy.
Its lead product Traumakine has been developed to treat acute respiratory distress syndrome. It is currently undergoing international phase III clinical trials after an open-label, early-phase trial showed promising results in the treatment patients with ARDS. The drug is known to function by enhancing lung CD73 expression and increasing production of anti-inflammatory adenosine, such that vascular leaking and escalation of inflammation are reduced. The U.S. Food and Drug Administration FDA has accepted the proposed protocol design for the next Traumakine study in March 2020. The phase III study is a comparison of efficacy in the treatment of patients with ARDS.
In 2020 Traumakine was selected to take part in the WHO Solidarity trial and REMAP-CAP trials to find drugs for the symptoms of Covid_19. Wikipedia
Apie „Faron Pharmaceuticals Oy“
Generalinis direktoriusMarkku Jalkanen
Darbuotojai36
Įkurta2003
Pagrindinė būstinė-
Sektorius-
Svetainėfaron.com